SCHEMBL3751633

SCHEMBL3751633

C=C(c1c[nH]cn1)c1cccc2cccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.46
MMP2 P08253 2/20 0.41
TSHR P16473 2/20 0.41
CHRM1 P11229 1/20 0.41
COMT P21964 1/20 0.41
ADRA1A P35348 1/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 3/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP3A4 P08684 2/20 0.39
GMNN O75496 1/20 0.39
TP53 P04637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CYP2D6 P10635 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747932 0.82 PARP1 (0.54) PARP1MMP2TSHRCHRM1COMT
SCHEMBL3751615 0.79 L3MBTL1 (0.41) HDAC8ALDH1A1KDM4EMAPTLMNA
SCHEMBL31285023 0.74 CYP2A6 (0.33) HDAC8
SCHEMBL31284853 0.74 LCLAT1 (0.31)
SCHEMBL3417739 0.74 TSHR (0.41) TSHRALDH1A1SMN1; SMN2TP53HTT
SCHEMBL3976340 0.73 TRPA1 (0.32) NPC1RAB9A
SCHEMBL5242510 0.72 PARP1 (0.59) PARP1MMP2TSHRCHRM1COMT
SCHEMBL19214855 0.71 PARP1 (0.68) PARP1MMP2TSHRCHRM1COMT
SCHEMBL3419181 0.70 KAT6A (0.35) PARP1HDAC8
SCHEMBL31285075 0.69 MRGPRX1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101052638-B As α24- (condensed cyclomethyl) -imidazole-2-thiones as adrenergic agonists ALLERGAN INC 2011-01-19 CN disclosed
US-7838545-B2 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. (US) 2010-11-23 US disclosed
US-20090176828-A1 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2009-07-09 US disclosed
US-7396849-B2 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as α2 adrenergic agonists ALLERGAN, INC. (US) 2008-07-08 US disclosed
CN-101052638-A As α24- (condensed cyclomethyl) adrenergic agonists-imidazole-2-thiones ALLERGAN INC (US) 2007-10-10 CN disclosed
EP-1791833-A2 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS Allergan, Inc. (US) 2007-06-06 EP disclosed
WO-2006036497-A2 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2006-04-06 WO disclosed
US-20060069144-A1 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069144-A1 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ADRB2, ADRA2C, ADRA2A PARP1 4448/4885MMP2 3256/4885TSHR 460/4885
US-20090176828-A1 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ADRB2, ADRA2C, ADRA2A PARP1 4356/4885MMP2 4204/4885TSHR 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.